Uterine carcinosarcoma: Contemporary clinical summary, molecular updates, and future research opportunity

医学 卡铂 肿瘤科 癌肉瘤 内科学 子宫内膜癌 转移 肉瘤 淋巴结切除术 存活率 无进展生存期 化疗 癌症 顺铂 病理
作者
Shinya Matsuzaki,Maximilian Klar,Shinya Matsuzaki,Lynda D. Roman,Anil K. Sood,Koji Matsuo
出处
期刊:Gynecologic Oncology [Elsevier BV]
卷期号:160 (2): 586-601 被引量:51
标识
DOI:10.1016/j.ygyno.2020.10.043
摘要

Uterine carcinosarcoma (UCS) is a biphasic aggressive high-grade endometrial cancer in which the sarcoma element has de-differentiated from the carcinoma element. UCS is considered a rare tumor, but its incidence has gradually increased in recent years (annual percent change from 2000 to 2016 1.7%, 95% confidence interval 1.2–2.2) as has the proportion of UCS among endometrial cancer, exceeding 5% in recent years. UCS typically affects the elderly, but in recent decades patients became younger. Notably, a stage-shift has occurred in recent years with increasing nodal metastasis and decreasing distant metastasis. The concept of sarcoma dominance may be new in UCS, and a sarcomatous element >50% of the uterine tumor is associated with decreased survival. Multimodal treatment is the mainstay of UCS. Lymphadenectomy, chemotherapy, and brachytherapy have increased in the past few decades, but survival outcomes remain dismal: the median survival is less than two years, and the 5-year overall survival rate has not changed in decades (31.9% in 1975 to 33.8% in 2012). Carboplatin/paclitaxel adjuvant chemotherapy improves progression-free survival compared with ifosfamide/paclitaxel, particularly in stages III-IV disease (GOG-261 trial). Twenty-six clinical trials previously examined therapeutic effectiveness in recurrent/metastatic UCS. The median response rate and progression-free survival were 37.5% and 5.9 months, respectively, after first-line therapy, but after later therapies, the outcomes were far worse (5.5% and 1.8 months, respectively). One significant discovery was that epithelial-mesenchymal transition (EMT) plays a pivotal role in the pathogenesis of sarcomatous dedifferentiation in UCS and that heterologous sarcoma is associated with a higher EMT signature compared with homologous sarcoma. Furthermore, next-generation sequencing has revealed that UCS tumors are serous-like and that common somatic mutations include those in TP53, PIK3CA, FBXW7, PTEN, and ARID1A. This contemporary review highlights recent clinical and molecular updates in UCS. A possible therapeutic target of EMT in UCS is also discussed.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
河畔发布了新的文献求助10
1秒前
吗喽完成签到,获得积分10
1秒前
1秒前
Yyan完成签到,获得积分10
1秒前
所所应助炙热的便当采纳,获得10
1秒前
2秒前
就这样发布了新的文献求助10
3秒前
西原的橙果完成签到,获得积分10
3秒前
3秒前
3秒前
深情安青应助疯狂的兰采纳,获得10
4秒前
4秒前
4秒前
跳跃的翼发布了新的文献求助30
5秒前
Lucien给伊斯坦布尔的鱼的求助进行了留言
5秒前
在下天池宫人间行走完成签到,获得积分10
6秒前
不想学习发布了新的文献求助10
6秒前
冬青完成签到 ,获得积分10
6秒前
含糊的鱼发布了新的文献求助10
6秒前
6秒前
Ansen发布了新的文献求助10
6秒前
科研通AI2S应助fu采纳,获得10
6秒前
澈哩发布了新的文献求助10
8秒前
dddhzzz发布了新的文献求助30
8秒前
Fox完成签到,获得积分20
8秒前
纸船完成签到,获得积分10
8秒前
9秒前
爆米花应助张志远采纳,获得10
9秒前
hyy完成签到,获得积分10
9秒前
韩麒嘉发布了新的文献求助10
9秒前
lzy完成签到,获得积分10
9秒前
mljever完成签到,获得积分10
9秒前
11秒前
huzi完成签到,获得积分10
12秒前
香蕉觅云应助过pass采纳,获得10
13秒前
系统提示发布了新的文献求助20
13秒前
可爱的田果果完成签到,获得积分10
13秒前
砰砰发布了新的文献求助10
13秒前
小二郎应助难过以晴采纳,获得10
13秒前
果果完成签到,获得积分10
13秒前
高分求助中
A new approach to the extrapolation of accelerated life test data 1000
ACSM’s Guidelines for Exercise Testing and Prescription, 12th edition 500
Picture Books with Same-sex Parented Families: Unintentional Censorship 500
Nucleophilic substitution in azasydnone-modified dinitroanisoles 500
不知道标题是什么 500
A Preliminary Study on Correlation Between Independent Components of Facial Thermal Images and Subjective Assessment of Chronic Stress 500
Phylogenetic study of the order Polydesmida (Myriapoda: Diplopoda) 360
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 3970683
求助须知:如何正确求助?哪些是违规求助? 3515337
关于积分的说明 11178055
捐赠科研通 3250580
什么是DOI,文献DOI怎么找? 1795357
邀请新用户注册赠送积分活动 875790
科研通“疑难数据库(出版商)”最低求助积分说明 805166